Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Cash & Equivalents (2020 - 2025)

RxSight's Cash & Equivalents history spans 6 years, with the latest figure at $19.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 91.59% year-over-year to $19.9 million; the TTM value through Dec 2025 reached $19.9 million, down 91.59%, while the annual FY2025 figure was $19.9 million, 91.59% down from the prior year.
  • Cash & Equivalents reached $19.9 million in Q4 2025 per RXST's latest filing, down from $227.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $237.2 million in Q4 2024 to a low of $8.8 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $103.9 million, with a median of $107.9 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: tumbled 92.43% in 2022, then skyrocketed 1260.65% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $156.4 million in 2021, then crashed by 92.43% to $11.8 million in 2022, then surged by 974.87% to $127.2 million in 2023, then skyrocketed by 86.48% to $237.2 million in 2024, then tumbled by 91.59% to $19.9 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Cash & Equivalents are $19.9 million (Q4 2025), $227.5 million (Q3 2025), and $223.5 million (Q2 2025).